Right of Reference and License Agreement - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) shares
GSK Agreement
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	$ 5.0
Specified clinical and regulatory milestones phase two clinical trial	2.5
GSK Agreement | Maximum
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	37.5
Specified sales milestone	60.0
CAMP4 Agreement
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	35.0
CAMP4 Agreement | Maximum
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	$ 35.0
Series B Convertible Preferred Stock | GSK Agreement
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Shares issued for asset acquisition | shares	12,500,000